| Catalog No. | HW762016 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Human |
|---|
| Isotype | IgG4-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Species | Human |
|---|
| Clonality | Monoclonal |
|---|
| Target | Small-inducible cytokine A11, SCYA11, Eotaxin, CCL11, Eosinophil chemotactic protein, C-C motif chemokine 11 |
|---|
| Endotoxin level | Please contact with the lab for this information. |
|---|
| Purity | >95% as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Accession | P51671 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
|---|
| Alternate Names | CAT-213, iCo-008, 375348-49-5 |
|---|
| Background | Bertilimumab (CAT 213; iCo-008) is a human monoclonal antibody targeting eotaxin-1 (CCL11). Bertilimumab has the potential for allergic disorders research.
• Genomic organization, complete sequence, and chromosomal location of the gene for human eotaxin (SCYA11), an eosinophil-specific CC chemokine., PMID:9169149
• Expression of rat I-TAC/CXCL11/SCYA11 during central nervous system inflammation: comparison with other CXCR3 ligands., PMID:15322564
• Independent predictive roles of eotaxin Ala23Thr, paraoxonase 2 Ser311Cys and beta-adrenergic receptor Trp64Arg polymorphisms on cardiac disease in Type 2 Diabetes--an 8-year prospective cohort analysis of 1297 patients., PMID:20536507
• Association between three single nucleotide polymorphisms in eotaxin (CCL 11) gene, hexanucleotide repetition upstream, severity and course of coronary atherosclerosis., PMID:22773402
• Variations in the human CC chemokine eotaxin gene., PMID:11781714
|
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
